A

Arvinas

D
ARVN
USD
-0.25
(-0.8929%)
Market Closed
14,186.00
Volume
-4.1
EPS
-
Div Yield
-5.469811
P/E
1,904,983,692.75
Market Cap
Today
-0.8929%
1 Week
4.895%
1 Month
9.901%
6 Months
-19.049%
12 Months
55.987%
Year To Date
-32.646%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
MRNA
MRNA
-0.985
(-1.921%)
USD
C
CRSP
1.15
(2.2656%)
USD
E
EDIT
-0.11
(-3.3537%)
USD
S
SGMO
0.645
(29.9304%)
USD
N
NTLA
-0.05
(-0.3113%)
USD
A
ALLO
-0.015
(-0.4666%)
USD
V
VYGR
-0.18
(-2.4759%)
USD
T
TXG
-1.45
(-8.2293%)
USD
B
BEAM
-0.53
(-1.991%)
USD

Title:
Arvinas

Sector:
Healthcare
Industry:
Biotechnology
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Do you need help or have a question?
Contact Us